JP2024537043A5 - - Google Patents
Info
- Publication number
- JP2024537043A5 JP2024537043A5 JP2024519270A JP2024519270A JP2024537043A5 JP 2024537043 A5 JP2024537043 A5 JP 2024537043A5 JP 2024519270 A JP2024519270 A JP 2024519270A JP 2024519270 A JP2024519270 A JP 2024519270A JP 2024537043 A5 JP2024537043 A5 JP 2024537043A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- modified oligonucleotide
- aqueous solution
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253933P | 2021-10-08 | 2021-10-08 | |
| US63/253,933 | 2021-10-08 | ||
| PCT/US2022/077766 WO2023060237A1 (en) | 2021-10-08 | 2022-10-07 | Methods and compositions for treatment of polycystic kidney disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537043A JP2024537043A (ja) | 2024-10-10 |
| JP2024537043A5 true JP2024537043A5 (https=) | 2026-04-27 |
Family
ID=84246040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519270A Pending JP2024537043A (ja) | 2021-10-08 | 2022-10-07 | 多嚢胞性腎疾患の治療のための方法及び組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240294913A1 (https=) |
| EP (1) | EP4413132A1 (https=) |
| JP (1) | JP2024537043A (https=) |
| KR (1) | KR20240073028A (https=) |
| CN (1) | CN118103510A (https=) |
| AR (1) | AR127325A1 (https=) |
| AU (1) | AU2022361062A1 (https=) |
| CA (1) | CA3234547A1 (https=) |
| CL (1) | CL2024000990A1 (https=) |
| CO (1) | CO2024004227A2 (https=) |
| IL (1) | IL311734A (https=) |
| MX (1) | MX2024003529A (https=) |
| TW (1) | TW202320808A (https=) |
| WO (1) | WO2023060237A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3234547A1 (en) | 2021-10-08 | 2023-04-13 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| WO2024215846A1 (en) * | 2023-04-12 | 2024-10-17 | Regulus Therapeutics Inc. | Modified oligonucleotide for treating polycystic kidney disease |
| IL324441A (en) * | 2023-06-16 | 2026-01-01 | Pyc Therapeutics Ltd | Compounds and methods for treating kidney diseases |
| WO2025193584A1 (en) * | 2024-03-11 | 2025-09-18 | Regulus Therapeutics Inc. | Compound for use in methods for treatment of polycystic kidney disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| NZ549535A (en) | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| CN101056991A (zh) | 2004-04-20 | 2007-10-17 | 基因耐克生物医学制品有限公司 | 检测ncRNA的方法 |
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| GB0523659D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| CA2648132C (en) | 2006-04-03 | 2019-05-28 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| JPWO2007126150A1 (ja) | 2006-04-27 | 2009-09-17 | 国立大学法人名古屋大学 | 癌の新規治療用組成物 |
| US20120283411A9 (en) | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP3192788A1 (en) | 2006-10-03 | 2017-07-19 | Arbutus Biopharma Corporation | Lipid containing formulations |
| US20090105174A1 (en) | 2007-04-20 | 2009-04-23 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| US8691965B2 (en) | 2007-06-14 | 2014-04-08 | Mirx Therapeutics Aps | Oligonucleotides for modulating target RNA activity |
| EP2623599B1 (en) | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| EP2217248B1 (en) * | 2007-10-29 | 2016-11-30 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of liver cancer |
| EP2268811A1 (en) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2009143403A1 (en) | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| EP2499239A1 (en) | 2009-11-11 | 2012-09-19 | Sanford-Burnham Medical Research Institute | METHOD FOR GENERATION AND REGULATION OF iPS CELLS AND COMPOSITIONS THEREOF |
| US20130236453A1 (en) | 2012-03-12 | 2013-09-12 | The Ohio State University | Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors |
| WO2013165320A1 (en) | 2012-05-04 | 2013-11-07 | Agency For Science, Technology And Research | Treating cancer by increasing expression of socs6 |
| SG11201508925WA (en) * | 2013-05-01 | 2015-11-27 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| EP3105327A4 (en) | 2014-02-12 | 2017-10-18 | Thomas Jefferson University | Compositions and methods of using microrna inhibitors |
| DK3340993T5 (da) | 2015-08-26 | 2024-10-07 | Regulus Therapeutics Inc | Forbindelse til anvendelse i fremgangsmåder til behandling af polycystisk nyresygdom |
| WO2018047148A1 (en) | 2016-09-12 | 2018-03-15 | Novartis Ag | Compounds for the inhibition of mirna |
| WO2018106568A1 (en) | 2016-12-05 | 2018-06-14 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
| IL322679A (en) * | 2016-12-05 | 2025-10-01 | Regulus Therapeutics Inc | Modified oligonucleotides for the treatment of polycystic kidney disease |
| US20200392503A1 (en) | 2016-12-05 | 2020-12-17 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| US20220380767A1 (en) | 2016-12-05 | 2022-12-01 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| EP4098746A4 (en) | 2020-01-31 | 2024-01-24 | National University Corporation Tokai National Higher Education and Research System | SINGLE-STRANDED POLYNUCLEOTIDE |
| CA3233014A1 (en) | 2021-10-08 | 2023-04-13 | Denis Drygin | Methods and compositions for avoiding off-target effects |
| CA3234547A1 (en) | 2021-10-08 | 2023-04-13 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| WO2024215846A1 (en) | 2023-04-12 | 2024-10-17 | Regulus Therapeutics Inc. | Modified oligonucleotide for treating polycystic kidney disease |
-
2022
- 2022-10-07 CA CA3234547A patent/CA3234547A1/en active Pending
- 2022-10-07 KR KR1020247010026A patent/KR20240073028A/ko active Pending
- 2022-10-07 MX MX2024003529A patent/MX2024003529A/es unknown
- 2022-10-07 JP JP2024519270A patent/JP2024537043A/ja active Pending
- 2022-10-07 AU AU2022361062A patent/AU2022361062A1/en active Pending
- 2022-10-07 TW TW111138235A patent/TW202320808A/zh unknown
- 2022-10-07 WO PCT/US2022/077766 patent/WO2023060237A1/en not_active Ceased
- 2022-10-07 CN CN202280066728.7A patent/CN118103510A/zh active Pending
- 2022-10-07 EP EP22800530.2A patent/EP4413132A1/en active Pending
- 2022-10-07 IL IL311734A patent/IL311734A/en unknown
- 2022-10-11 AR ARP220102755A patent/AR127325A1/es unknown
-
2024
- 2024-03-20 US US18/610,891 patent/US20240294913A1/en active Pending
- 2024-04-03 CL CL2024000990A patent/CL2024000990A1/es unknown
- 2024-04-05 CO CONC2024/0004227A patent/CO2024004227A2/es unknown
-
2025
- 2025-02-12 US US19/052,052 patent/US12559750B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537043A5 (https=) | ||
| JP2023098946A5 (https=) | ||
| ES2284250T3 (es) | Formulaciones para la prevencion o el tratamiento de enfermedades que afectan a la membrana mucosa o la piel, o para la prevencion del embarazo. | |
| ES2253395T3 (es) | Uso de sulfato de celulosa y otros polisacaridos sulfatados para prevenir y tratar infecciones por virus del papiloma. | |
| TWI396561B (zh) | 容許活性成分改質釋放之可分割之蓋倫氏型式 | |
| JP2025161856A5 (https=) | ||
| JP2020517653A5 (https=) | ||
| JPWO2023195530A5 (https=) | ||
| JP2002544241A5 (https=) | ||
| CN1185110A (zh) | 协同组合物 | |
| JP2019089796A5 (https=) | ||
| JP2013500977A5 (https=) | ||
| EP3577129A1 (en) | Methods for treating fungal infections | |
| JP2002528502A5 (https=) | ||
| JP2017501227A (ja) | アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 | |
| JP2009500045A5 (https=) | ||
| JP2003520252A5 (https=) | ||
| CN111467348A (zh) | 一种n-(噻唑-2-基)-3-(哌嗪-1-基)丙酰胺类衍生物在药物制备中的应用 | |
| US8367683B2 (en) | Composition and method for treatment of warts | |
| JP2021525758A5 (https=) | ||
| JP2005526713A5 (https=) | ||
| JP2021511352A5 (https=) | ||
| JP3282832B2 (ja) | 持続性錠剤 | |
| JP2006520343A5 (https=) | ||
| CN104771384B (zh) | 紫草素的医药用途 |